improvement of vascular invasion scoring in stage i...
TRANSCRIPT
Improvement of vascular invasion scoring in stage I testicular non-seminomas
to predict relapse during surveillance after orchiectomy
João Lobo
Hans Stoop, Ad Gillis, Leendert HJ Looijenga, J. Wolter Oosterhuis
No conflicts of interest8th September 2019
Lobo et al. Hum Pathol 2018TGC
Ts:
het
ero
gen
eity
& c
ha
llen
ges
Lobo et al. Int J Mol Sci 2019TGC
Ts:
het
ero
gen
eity
& c
ha
llen
ges “Germ cell tumors are at the crossroads between
developmental biology and cancer"
1% male cancer
Decreasing mortality
Most curable solid neoplasms
Same cytogenetic background (i12p) and low mutational burden
Most common cancer in Caucasian men 15—44yo
Rising incidence
15-20% disseminated disease recurs (poor prognosis)
Cisplatin resistance
Iatrogeny (young patients)
Better disease biomarkers urgently neededW
hy
focu
sin
g o
n T
GC
Ts?
1% male cancer
Decreasing mortality
Most curable solid neoplasms
Same cytogenetic background (i12p) and low mutational burden
Most common cancer in Caucasian men 15—44yo
Rising incidence
15-20% disseminated disease recurs (poor prognosis)
Cisplatin resistance
Iatrogeny (young patients)
Better disease biomarkers needed
Wh
y fo
cusi
ng
on
TG
CTs
?
Costa and Lobo et al. Epigenomics 2017
Va
scu
lar
inva
sio
na
s a
bio
ma
rker
Prognostic marker
Metastases, recurrence
TNM (pT2, stage IA)
Patient stratification
Inter-observer agreement in reporting
Not ideal
Most common disagreement upon centralized review
Subjectivity, artifacts, criteria…
Immunohistochemistry and type of vessel
No formal recommendation (ISUP)
Lack of data
Aim
sa
nd
Met
ho
do
log
y
1
• Inter-observer agreement in VI scoring on H&E
2
• Additional value of adding IHC for vascular markers
3
• Additional value of characterizing the type of vessel invaded
“Clean” cohort
Strict inclusion criteria
H&E + IHC panel (D2-40, CD31, FVIII)
Scoring by 3 independent
observers
✓ Consecutively diagnosed NS patients✓ Stage I✓ Only surveillance after orchiectomy
✓ 2 FFPE samples✓ >1cm2 tumor✓ Tumor-parenchyma interface
✓ Dedicated to TGCT pathology
✓ D2-40: lymph vessels✓ CD31, FVIII: blood vessels
Co
ho
rtch
ara
cter
iza
tio
nVariables
Patient cohort
(n=52)Age [years (median, IQR)] 31 (24-35)Laterality (n, %)
Right 21/52 (40.4)Left 31/52 (59.6)
Pre-operative serum tumor markers
(n, %)Within normal range 20/52 (38.5)Elevated 32/52 (61.5)
Histologic subtypes (n, %)Pure embryonal carcinoma 5/52 (9.6)Pure postpubertal-type teratoma 2/52 (3.8)Mixed tumor, without seminoma 21/52 (40.4)Mixed tumor, with seminoma 24/52 (46.2)
Multifocality (n, %)Absent 50/52 (96.2)Present 2/52 (3.8)
Largest tumor size [cm (median, IQR)] 3.5 (2.5-5.4)Rete testis invasion (n, %)
Absent 30/42 (71.4)Present, stromal 9/42 (21.4)Only pagetoid spread of GCNIS 3/42 (7.1)
Vascular invasion (n, %)Absent 25/50 (50.0)Present 25/50 (50.0)
VariablesPatient cohort
(n=52)Relapse (n, %)
No 21/52 (40.4)Yes 31/52 (59.6)
Type of relapse (n, %)Early 28/31 (90.3)Late 3/31 (9.7)
Site of relapse (n, %)Only serum markers 6/31 (19.4)Serum markers + PAoLN 14/31 (45.2)Only PAoLN 4/31 (12.9)Only Lung 2/31 (6.5)Serum markers + Lung + PAoLN 4/31 (12.9)Serum markers + Liver + Lung + PAoLN 1/31 (3.2)
Treatment performed for relapses (n, %)Only chemotherapy 26/31 (83.9)Chemotherapy + RPLND 5/31 (16.1)
Vital status at last follow-up (n, %)A-NED 50/52 (96.2)D-NED 1/52 (1.9)DFD 1/52 (1.9)
Pro
gn
ost
icva
lue
On multivariable analysis (age, tumor size, serum tumor markers, rete testis invasion)
VI showed an independent impact in predicting disease relapse
(HR 3.163, 95% CI 1.31-7.63)
Inte
r-o
bse
rver
ag
reem
ent
Testicular germ cell tumor-dedicated pathologists’ assessment of vascular invasion
Agreement
Cohen’s Kappa = 0.54 (p<0.001)
Pathologist 3
Absent Present
Pathologist 1
Absent 23 4
Present 8 17
Agreement
Cohen’s Kappa = 0.50 (p<0.001)
Pathologist 2
Absent Present
Pathologist 1
Absent 22 5
Present 8 17
Agreement
Cohen’s Kappa = 0.49 (p<0.001)
Pathologist 2
Absent Present
Pathologist 3
Absent 24 7
Present 6 15
Agreement among TGCT-dedicated pathologists was moderate, as
reported(κ 0.49-0.54)
Per
form
an
ce in
pre
dic
tin
gre
lap
se
Vascular invasion
scoring
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
H&E (consensus) 61.3 85.7 86.4 60.0 71.2
Immunohistochemistry
(D2-40 + FVIII +
CD31)
71.0 71.4 78.6 62.5 71.2
IHC resulted in increase in sensitivity and decrease in
specificity
IHC upgraded 8 cases of “absent VI on H&E” → 3 of them developed
relapseIHC downgraded 2 cases of
“present VI on H&E” → both did not develop relapse
Va
scu
lar
inva
sio
n:
cha
llen
ges
Mis
sed
ca
ses
on
H&
E a
sses
smen
t
Va
scu
lar
inva
sio
n m
imic
kers
H&E
D2-40
CD31
FVIII
H&E
D2-40
CD31
FVIII
Typ
eo
fve
ssel
Vascular invasion scoring No relapse (n) Relapse (n)
IHC showing LVI only 3 12
IHC showing BVI only 3 2
IHC showing LVI + BVI 0 8
“Double vascular invasion patients”: 100% accuracy in predicting disease
relapse
Active selection for adjuvant treatment instead of surveillance?
Co
ncl
usi
on
s
1
• Inter-observer agreement in VI scoring on H&E
2
• Additional value of adding IHC for vascular markers
3
• Additional value of characterizing the type of vessel invaded
Moderate among TGCT-dedicatedpathologists, but can be improved
Increase in sensitivity for predictingdisease relapse
Identification of high-risk patients
(both LVI and BVI)
Co
ncl
usi
on
s
Indication for routine IHC use?
Endpoint: relapse-free survival
Large, prospective studies, with IHC
FUTURE
Supervising team:Rui Henrique
Carmen JerónimoLeendert Looijenga
Department of PathologyÂngelo Rodrigues
Paula LopesMariana Cantante
Rita Guimarães
Cancer Biology & Epigenetics GroupVera Gonçalves
Daniela Barros SilvaSandra Nunes
Ethics approval: CES IPO 1/2018
IPO Porto
The Netherlands
Project Funding: POCI-01-0145-FEDER-29043Doctoral Grant: SFRH/BD/132751/2017
Urology ClinicJorge Oliveira
Joaquina MaurícioIsaac Braga
Department of EpidemiologyLuís Antunes
PMC Utrecht (Group Looijenga)Ad Gillis
Annette van den BergRachita Lahri
Dennis Timmerman
Erasmus MC Rotterdam & LEPO
Wolter OosterhuisLambert Dorssers
Hans StoopWillem Boellaard
Thank you for your attention!